HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After US FDA Finds ‘Particularly Concerning’ GMP Problems, Homeopathic Firm Continues OTC Sales

Executive Summary

A warning letter submitted by FDA Office of Regulatory Affairs’ Division of Pharmaceutical Quality Operations I in New Jersey notes that Homeocare Laboratories indicated to agency officials that it no longer is manufacturing OTC drugs.

You may also be interested in...



2020 In Review: Despite Pandemic, The US FDA Issued Just 20% Fewer Drug GMP Warning Letters

The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.

US COVID-19 Fraud: Oleander Stops Viral Duplication, Oral Rinse Delivers 30-Second Cure

Online claims and social media posts lead to warnings to Phoenix Biotechnology and Avila Herbals for claiming oleander homeopathic at 4X concentration can interfere with COVID-19 and other viruses’ duplication, and Rowpar Pharmaceuticals about a rapid cure provided by oral rinses and spray.

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

Related Content

Topics

UsernamePublicRestriction

Register

RS150186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel